DaVita HealthCare Partners Inc., the parent company of dialysis provider DaVita, has named Garry E. Menzel, PhD, chief financial officer, effective after Sept. 30. He will act as senior vice president of finance until then.

Menzel, 48, most recently held the positions of Chief Operating Officer and Chief Financial Officer at Regulus Therapeutics Inc., a publicly-traded biopharmaceutical company. Prior to joining Regulus in 2008, he had a 14-year career on Wall Street where he was a managing director and global head of life sciences for Credit Suisse and a managing director and global head of biotechnology for Goldman Sachs. Menzel also spent several years as a strategy consultant for Bain & Company. 

Menzel earned a B.Sc. in biochemistry from the Imperial College of Science & Technology in London, England, a PhD in molecular biology from the University of Cambridge, England, and a Masters in Business Administration from the Stanford Graduate School of Business. 

Jim Hilger, who has served as Interim Chief Financial Officer since 2012, and acting chief financial officer from 2007 to 2008, will continue in his role as the company’s chief accounting officer, a position he has held since 2010.